INTRODUCTION
Bacterial resistance to antibacterial agents or antibiotics is of grave concern in the medical community, as many species of bacteria have evolved resistance to certain antibiotics and synthetic agents. Therefore, there could be a rapidly growing global crisis in the clinical management of life-threatening infectious diseases caused by multidrug-resistant strains of the Gram-positive pathogens like Streptococcus, Enterococcus, and Staphylococcus, and Gram-negative pathogens like Escherichia, Salmonella, and certain Pseudomonas strains. Especially the emergence of multidrug-resistant strains of Gram-positive bacterial pathogens such as methicillin-resistant Staphylococcus aureus and Staphylococcus epidermis and vancomycin-resistant Enterococcus is an alarming problem of ever increasing significance. [1] [2] [3] [4] To meet this crisis successfully, many researchers across the globe are working to unearth new compounds which can selectively attack novel targets in microorganisms. Hence, the development of novel, potent, and unique antibacterial agents is the preeminent way to overcome bacterial resistance and develop effective therapies. 5 The compounds possess benzothiazole nucleus in their structure are involved in research aimed at evaluating new chemotherapeutically active agents: such as antimicrobial [6] [7] [8] [9] a topical carbonic anhydrase inhibitor, 10 a cyclooxygenase inhibitor, 11 antitubercular, 12, 13 antinematode, 14 a dual inhibitor of thromboxane A 2 synthetase and 5-lipoxygenase 15 , a selective and reversible inhibitor of monoamine oxidase type A (MAO-A), 16 antiallergic, 17 multi-drug resistance cancer cell activities with inhibiting activity on eukaryotic topoisomerase II enzyme in cell-free system [18] [19] [20] and antitumor agents. [21] [22] [23] Currently, a new series of benzothiazoles have been synthesized as antitumor agents and showed potent inhibitory activity against human breast cancer cell lines in vitro and in vivo. 21 Among them, lysyl-amide of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (Formula 1) had been selected for phase 1 clinical evaluation. 22 In the last years, we reported the synthesis of several 2-substitutedbenzothiazole derivatives as the anti- microbial agents 7, 8 as seen in Formula 2. According to these studies the compounds were found to have inhibitory effect with MIC value of 3.12-50 µg/ml against some of Gram-positive, Gram-negative bacteria and Candida albicans as yeast. Among the tested compounds, 2-(phenoxymethyl)benzothiazole was found the most active derivative at a MIC value of 3.12 µg/ml against the tested S. aureus. 8 Moreover, the same compound was found very potent as an eukaryotic topoisomerase II inhibitor exhibiting a better inhibitor activity than reference drug [18] [19] [20] etoposide. Currently, we reported the synthesis and the antimicrobial activity of 2-[4-(4-substituted-benzamido/phenylacetamido)phenyl]benzothiazole derivatives (7a-7k). 24 In continuation to our ongoing research work on new 2-(4-carboxamido-benzyl / phenyl)benzothiazole derivatives, herein, we described the synthesis and in vitro antimicrobial activity of novel 2-[4-(4-substitutedbenzamido / phenylacetamido / 3-phenylpropionamido) benzyl / phenyl]benzothiazoles (6a−6w) (Formula 3) against different Gram positive (Staphylococcus aureus, Bacillus subtilis) and Gram-negative (Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli) bacteria with their drug-resistant isolates as well as the yeast C. albicans in comparison with several control drugs, including structure-activity relationship (SAR) studies.
EXPERIMENTAL Chemistry
The chemicals were purchased from the commercial venders and were used without purification. The reactions were monitored and the purity of the products was checked by thin layer chromatography (TLC). Silicagel HF254 chromatoplates (0.3 mm) were used for TLC and the solvent systems were n-hexan:ethyl acetate (2:1) for 2-(4-aminobenzyl/phenyl)benzothiazole (3) and chloroform:methanol (20:1) for compounds 6a−6w. Melting points were taken on a Buchi SMP 20 capillary apparatus and are uncorrected. IR spectra were recorded by FT/IR-420 in KBr discs. 
23,25
General procedure for the synthesis of compounds (6a-6w)
The result products, 2-[4-(4-substitutedbenzamido/phenylacetamido/3-phenyl propionamido)benzyl/phenyl]-benzothiazole derivatives (6a−6w) were synthesized by heating thionyl chloride (0.3 ml) and appropriate carboxylic acid (4) (1 mmol) in benzene (0.5 ml) at 80 ºC for 3h, and then excess thionyl chloride was removed in vacuo (Scheme 2). The residue was dissolved in ether (1 ml) and solution added during 1h to a stired, ice-cold mixture of 2-(4-aminobenzyl/phenyl)benzothiazole (1 mmol), sodium bicarbonate (2 mmol), diethylether (1 ml) and water (1 ml). 26 The mixture was kept stirred overnight at room temperature and then filtered. After the precipitate was washed with water, 2N HCl and water. Ethanol was used for recrystallization and crystals are dried in vacuo. Bacterial susceptibility testing was performed according to the guidelines of CLSI M100-S16. 28 The bacterial suspensions used for inoculation were prepared at 10 5 cfu/ml by diluting fresh cultures at MacFarland 0.5 density (10 7 cfu/ml). Suspensions of the bacteria at 10 5 cfu/ml concentration were inoculated to the twofold diluted solution of the compounds. There were 10 4 cfu/ml bacteria in the wells after inoculations. MHB was used for diluting the bacterial suspension and for twofold dilution of the compound. 80 % DMSO-20 % EtOH, methanol, DMSO, PBS, pure microorganisms and pure media were used as control wells. A 10 µl bacteria inoculum was added to each well of the microdilution trays. The trays were incubated at 37 o C and MIC endpoints were read after 24 h of incubation.
2-[4-(benzamido)phenyl]benzothiazole (6a)

2-[4-(4-sec-butoxybenzamido)phenyl]benzothiazole (6b)
Yield
2-[4-(phenylacetamido)phenyl]benzothiazole (6c)
2-[4-(4-nitrophenylacetamido)phenyl]benzothiazole (6d)
2-[4-(4-nitrobenzamido)benzyl]benzothiazole (6k)
2-[4-(4-ethylbenzamido)benzyl]benzothiazole (6l)
2-[4-(4-tert-butylbenzamido)benzyl]benzothiazole (6m)
2-[4-(4-nitrophenylacetamido)benzyl]benzothiazole (6s)
2-[4-(4-methylphenylacetamido)benzyl]benzothiazole (6t)
2-[4-(4-methoxyphenylacetamido)benzyl]benzothiazole (6u)
2-[4-(3-phenylpropanamido)benzyl]benzothiazole (6v)
2-[4-(3-(4-metoxyphenyl)propanamido)benzyl]benzothiazole (6w)
C. albicans was subcultured in SDA plates, and incubated at 35 o C for 24-48 h prior to antifungal susceptibility testing. Susceptibility testing was performed in RPMI-1640 medium with L-glutamine buffered pH 7 with 3-[N-morpholino]-propansulfonic acid (MOPS) and culture suspensions were prepared through the guideline of CLSI M27-A3. 29 Yeast suspensions were prepared according to McFarland 0.5 density and a working suspension was made by a 1:100 dilution followed by a 1:20 dilution of the stock suspension (2.5×10 3 CFU/ml). A 10 µl yeast inoculum was added to each well of the microdilution trays. The trays were incubated at 35 o C and MIC end points were read after 48 h of incubation.
All organisms were tested in triplicate in each run of the experiments. The lowest concentration of the compound that completely inhibits macroscopic growth was determined and minimum inhibitory concentrations (MICs) were reported in Table 1 .
Croat. Chem. Acta 86 (2013) 223. showing as the same activity compared to gentamycin sulfate. The derivative, 6j showed more potent inhibitory effect with a MIC value of 6.25 μg/ml than the other compounds against S. aureus.
Moreover, most of the synthesized compounds exhibited a moderate antifungal activity for C. albicans with MIC values between 12.5-25 μg/ml except 6p. It can be concluded that the compound is holding a fluorine atom on position R of phenyl ring at phenylacetamido moiety instead of benzamido play a decisive role for the antifungal activity against C.albicans.
CONCLUSION
Because of the need of new antibacterial drugs active against the multi-drug resistance bacteria, herein, we synthesized 2-[4-(4-substitutedbenzamido / phenylacetamido / phenylpropionamido) benzyl / phenyl]benzothiazole derivatives (6a-6w) as a new antimicrobial agents in order to be able to contribute to the antimicrobial researchers.
In according to our present study, it can be proposed, that 2-phenylbenzothiazole moiety was found to be more important than 2-benzylbenzothiazole for enhancing potency against Gram-negative bacteria especially the drug-resistant P. aeruginosa isolate. Furthermore, benzamide moiety at position 2 of benzothiazole ring was more important for increasing potency against the Gram-positive S. aureus.
These observations provide some predictions in order to design further antimicrobial active compounds prior to their synthesis following with QSAR and molecular modelling studies.
